KAHR Announces Positive Results for DSP107 in Combination with Atezolizumab in Metastatic Colorectal Cancer Patients

Strategic Insights -

KAHR, a clinical-stage biotech company, announced positive results for the Phase 2 dose expansion cohort of DSP107, a first-in-class bi-specific 4-1BB T-cell engager, in combination with atezolizumab, an anti-PD-L1 cancer immunotherapy, in patients with 3rd line microsatellite stable metastatic colorectal cancer (MSS-CRC). The combination demonstrated anti-tumor activity and extended survival, including in patients with liver metastases. The results will be presented in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Takeaways:

  • DSP107, a bi-specific 4-1BB T-cell engager, demonstrated anti-tumor activity and extended survival in combination with atezolizumab in patients with 3rd line microsatellite stable metastatic colorectal cancer (MSS-CRC).
  • The combination was well-tolerated, and its efficacy was observed in patients with liver metastases, a devastating disease with significant unmet medical need.
  • The study enrolled 30 patients, treated with DSP107 infusions (10 mg/kg) and atezolizumab (1200 mg) every three weeks, until disease progression.
  • The primary objective of the study was to evaluate the safety and tolerability of DSP107 in combination with atezolizumab, and the secondary objective was to assess the preliminary efficacy of the combination.
  • DSP107 binds to CD47, a protein expressed on the surface of cancer cells, converting it into a 4-1BB signal that attracts and activates adaptive immune cells.
  • The combination is particularly relevant in colorectal cancer, where 70% of metastatic patients have liver metastases and express CD47 in response to first- and second-line chemotherapy treatments.
  • DSP107 is being tested in Phase 2 expansion cohort in 2L/3L PD1-experienced NSCLC and has shown promise in treating MSS-CRC patients, a challenging disease with limited treatment options.

Statistics:

  • 30 patients were enrolled in the Phase 2 dose expansion cohort of DSP107 in combination with atezolizumab.
  • 70% of metastatic colorectal cancer patients have liver metastases.
  • DSP107 uses CD47 overexpression as a tumor anchor and binds to CD47 to engage the immune system in a wholistic anti-cancer response.
  • 2025 American Society of Clinical Oncology (ASCO) Annual Meeting will feature an oral presentation on the positive results of DSP107 in combination with atezolizumab.

Sources:

  • NCT04440735 - clinical trial number for the Phase 2 dose expansion cohort of DSP107 in combination with atezolizumab.
  • . (2025, May 27). KAHR Announces Positive Results for DSP107 in Combination with Atezolizumab in Metastatic Colorectal Cancer Patients. PR Newswire.
  • American Society of Clinical Oncology (ASCO) (2025). 2025 ASCO Annual Meeting.